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Abstract: Identifying differential expression of genes in psoriatic and healthy skin by microarray 
data analysis is a key approach to understand the pathogenesis of psoriasis. Analysis of more 
than one dataset to identify genes commonly upregulated reduces the likelihood of false posi-
tives and narrows down the possible signature genes. Genes controlling the critical balance 
between T helper 17 and regulatory T cells are of special interest in psoriasis. Our objectives 
were to identify genes that are consistently upregulated in lesional skin from three published 
microarray datasets. We carried out a reanalysis of gene expression data extracted from three 
experiments on samples from psoriatic and nonlesional skin using the same stringency threshold 
and software and further compared the expression levels of 92 genes related to the T helper 17 
and regulatory T cell signaling pathways. We found 73 probe sets representing 57 genes com-
monly upregulated in lesional skin from all datasets. These included 26 probe sets represent-
ing 20 genes that have no previous link to the etiopathogenesis of psoriasis. These genes may 
represent novel therapeutic targets and surely need more rigorous experimental testing to be 
validated. Our analysis also identified 12 of 92 genes known to be related to the T helper 17 
and regulatory T cell signaling pathways, and these were found to be differentially expressed 
in the lesional skin samples.
Keywords: psoriasis, gene array analysis, gene expression profiling
Introduction
Psoriasis is a common, chronic, inflammatory, relapsing skin disease mediated by 
T cells, dendritic cells, and several inflammatory cytokines.1,2 Recent advances in 
our knowledge of mechanisms linking innate and adaptive immunity have led to 
reconsideration of the roles of key players in the pathogenesis of the disease with 
many uncertainties.3
Studies of gene expression profiling provide valuable insights into the patho-
mechanisms involved in psoriasis. The transcriptome from skin biopsies was previ-
ously analyzed on microarrays using the 7,000-oligonucleotide array HU6800, the 
approximately 12,600 element array U95A, the approximately 63,000 probe sets 
Affymetrix U95A–E arrays, and cDNA arrays.4–7 As a result, a number of changes in 
gene and/or protein expression have been detected in psoriasis, eg, interleukin (IL)-1 
and tumor necrosis factor alpha (TNF-α), which were reported to be upregulated with 
subsequent activation of the NF-κB pathway.5 It was also noted that Wnt5a and other 
genes involved in the Wnt signaling pathway are differentially expressed in psoriatic 
plaques. However, their functional contribution to the pathophysiology of psoriasis 
needs to be elaborated.8 Recently, concerns regarding false positives and/or missing 
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key signals from microarray data have arisen due to the large 
size of the data output, the background noise inherent in the 
technology, and the financial constraints on the number of 
replicates.9 As a result, reanalysis of published microarray 
data has become a useful extension of the technology.
Recent studies have shown the crucial role of the 
T helper 17 (T
H
17) cell population in development of the 
disease.10 T
H
17 cells are activated by the dendritic cell 
cytokine IL-23, can produce IL-17, IL-22, and TNF-α, and 
have many other downstream proinflammatory effects.11 
Conversely, T regulatory (T
Reg
) cells suppress effector T cell 
responses and prevent their potentially pathogenic effects.12 
T
Reg
 cells are characterized by expression of the transcription 
factor Forkhead box P3. Differentiation of both T
H
17 and 
T
Reg
 cells can require transforming growth factor-beta, and 
the balance between these cells may be mediated by IL-6. 
The production of IL-6 during inflammatory reactions makes 
Forkhead box P+ T
Reg
 nonfunctional and allows effector cells 
to induce inflammation in the target organ.13,14 However, 
much remains to be elucidated concerning the relationship 
between proinflammatory and regulatory cells.10
This study aims to comprehensively reanalyze microarray 
gene expression data extracted from three different experi-
ments deposited in the GEO datasets,8,15,16 according to the 
same criteria. All experiments included skin biopsies from 
lesional and nonlesional skin, while only two experiments 
include additional samples from healthy control skin. By 
reporting genes that are found to be upregulated as a result 
of the disease in more than one experiment, the possibility of 
false positives is reduced and the output gene list is refined. We 
also related our findings to the expression profile of 92 genes 
(Table 1) involved in the T
H
17 and T
Reg
 regulatory pathways.
Materials and methods
gene microarray experiments
Data from three experiments with GEO accession numbers, 
GSE6710, GSE13355, and GSE14905, were extracted from 
the free PubMed domain (http://www.ncbi.nlm.nih.gov/
gds?term=psoriasis) for further analysis. The GSE6710 
experiment8 includes data from lesional and nonlesional 
skin samples from 13 individuals with psoriasis and used 
parent platform GPL96 Affymetrix Human Genome U133A 
GeneChip® (Affymetrix, Santa Clara, CA, USA). In the 
GSE13355 experiment,15 the parent platform GPL570 Affyme-
trix Human Genome U133 PLUS 2.0 GeneChip was used 
and a total of 180 skin samples were profiled, encompassing 
biopsies from the healthy skin of 64 control subjects and 
biopsies from the involved and  uninvolved skin of 58 patients 
with psoriasis. In the GSE14905 experiment,16 the parent 
platform GPL570 Affymetrix Human Genome U133 Plus 2.0 
GeneChip was used and a total of 82 skin samples were pro-
filed (21 normal, 28 uninvolved skin, and 33 lesional skin).
Microarray data analyses
Data files from the above experiments were analyzed with 
GeneSpring GX11 software (Agilent Technologies, Santa 
Clara, CA, USA). Ambiguous samples (three samples from 
GSE6710 and one sample from each of GSE13355 and 
GSE14905) were excluded by running quality control on 
each dataset. The data were filtered by expression within 
the 20–100th percentile, log-transformed, normalized using 
the Robust Multichip Average algorithm, and baseline con-
verted to the median of all samples. Differential expression in 
lesional versus nonlesional skin samples was compared using 
paired Student’s t-test statistics with a P-value cutoff #0.05 
and a fold change $2.0. To discern further the biological 
meaning of the output gene lists, we functionally annotated 
significantly expressed genes on human Kegg pathways using 
Database for Annotation, Visualization and Integrated Dis-
covery (DAVID)17 version 6.7 and the HT Human Genome 
U133 Plus set as background.
For identification of possible interactions between genes 
of potential importance for the development of psoriasis, 
network analysis was performed with NetBox 1.0 (cBio, 
Memorial Sloan-Kettering Cancer Center, New York, NY, 
USA) (http://cbio.mskcc.org/tools/netbox/netbox.tar.gz). 
This tool uses human interactions derived from literature-
Table 1 genes involved in the T helper 17 and regulatory T cell 
signaling pathways that were specifically interrogated in our 
analysis
surface molecules cD28, cD34, cD3D, cD3e, cD3g, 
cD4, cD25, cD127, cD40lg, cD8a, 
icaM1, icOs, isg20, cTla4
chemokines ccl1, ccl2, ccl20, ccl22, ccl7, 
cD247, cX3cl1, cXcl1, cXcl12, 
cXcl2, cXcl5, cXcl6, il8, MMP13, 
MMP3, MMP9, ccr4, ccr6
cytokines csF2, csF3, iFng, il10, il12B, il13, il15, 
il17a, il17c, il17D, il17F, il18, il1a, 
il1B, il2, il21, il22, il23a, il25, il27,  
il3, il4, il5, il6, TgFB1, TnFa, TnFB
cytokine receptors il12rB1, il12rB2, il17rB, il17rc, 
il17rD, il17re, il23r, il6r, il7r
signaling pathway molecules 
and transcriptional factors
cacYBP, ceBPB, clec7a, eDg1, 
FOXP3, gaTa3, JaK1, JaK2, nFaTc2, 
nFKB1, rOrc, sOcs1, sOcs3, sTaT3, 
sTaT4, sTaT5a, sTaT6, sYK, TBX21, 
TiraP, Tlr4, TraF6, YY1, T-BeT
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curated data sources for prediction of interaction of genes 
in a submitted gene list. NetBox is preloaded with a human 
interaction network derived from four literature-curated data 
sources, including the Human Protein Reference Database,18 
Reactome,19,20 NCI-Nature Pathway Interaction Database,21 
and Memorial Sloan-Kettering Cancer Center Cancer Cell 
Map, and provides the netAnalyse.py method for network 
analysis, which was described by Cerami et al22 in 2010. The 
netAnalyse.py method settings applied during analysis were 
shortest path threshold =1 and P-value threshold =0.05. The 
resultant networks were then imported into Cytoscape for 
further editing and analysis.23
Results
Reanalysis of three published microarray datasets8,15,16 revealed 
a number of probe sets that are differentially expressed 
(upregulated and/or downregulated) in psoriatic lesional versus 
nonlesional skin from each experiment, and the Venn diagram 
in Figure 1 illustrates the intersections between the three 
experiments. In general, a total of 73 probe sets representing 
57 genes were found common to the three datasets and were 
significantly upregulated in the psoriatic lesions (Figure 1, 
with a complete list in Tables S1 and S2). Of these probe sets, 
only 26 representing 20 genes have no previous reported link 
to the etiopathogenesis of psoriasis (Table S2).
We then studied the transcriptional activity underly-
ing the dynamic interplay between the CD4+ T
H
17 and 
CD4+CD25highFoxP3+T
Reg
 cell lineages in the skin of psoriatic 
patients from the three above experiments. This interplay has 
recently been linked to the etiopathogenesis of psoriasis and 
some other autoimmune diseases.10,24
A list of 92 genes (Table 1) that are likely to be involved 
in the T
H
17 and T
Reg
 signaling pathways was prepared. In the 
first instance, we searched for the differential expression of 
these genes in the three experiments.
A total of 12 genes were found to be differentially 
expressed (upregulated/downregulated) in the lesional skin 
samples with a false discovery rate of ,0.01 and an absolute 
fold change .2 in at least one of the datasets (Tables 2–4). 
In the data extracted and analyzed from the GSE6710 
experiment,8 five probe sets representing four genes were 
found to be differentially expressed in the psoriatic lesions, 
with CD34 being the only example to be downregulated 
(Table 2). The corresponding profile for the data from 
GSE1335515 is a total of nine probe sets/genes that are all 
upregulated in the lesional versus nonlesional skin (Table 3). 
In the GSE14905 dataset,16 a total of 12 probe sets represent-
ing 11 genes were found to be significantly upregulated in 
the lesional versus nonlesional skin (Table 4).
Network analysis was performed on the significantly 
changed genes reported in Tables 2–4, S1, and S2. Genes 
associated with T
H
17/T
Reg
 reported in Table 1 were added to 
this list to aid identification of a possible connection between 
these genes. The resultant network was then imported into 
Cytoscape for further analysis.23 In order to depict possible 
interactions between genes reported in Tables 2–4, S1, and 
S2, the nodes for these genes in the network were enlarged 
and were colored orange, red (upregulated in psoriasis), or 
green (downregulated in psoriasis). Identified direct interac-
tions of these genes, which were predicted by the network 
analysis, were marked as connecting red lines between these 
nodes (Figure 2).
GSE13355 – les vs nonles
286 entities (210/76)
GSE6710 – les vs nonles
152 entities (88/64)
GSE14905 – les vs nonles
348 entities (237/111)
30/15
105/30
2/5
73/26
4/9
9/24
55/46
Figure 1 Venn diagram illustrates the number of probe sets that show significant higher expression/number of those showing significant lower expression in lesional versus 
nonlesional skin from the three experiments, ie, gse6710 (upper right circle), gse13355 (upper left circle), and gse14905 (lower circle). The intersecting regions represent 
probe sets that are common in the specific experiments.
Abbreviations: GSE, GeneSys Export file; les, lesional; vs, versus; nonles, nonlesional.
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Nodes in these networks were colored according to fold 
change (green downregulated, yellow-orange-red upregu-
lated) and size of the node indicates relative significance 
(larger being more significant) (Figures S1–S3).
Discussion
This study confirmed previously reported and newly identi-
fied changes in gene transcription in psoriatic skin that might 
 contribute to the etiopathogenesis. Our approach was to reana-
lyze the microarray raw data deposited in the GEO datasets 
from three different experiments.8,15,16 Simple comparison of 
the available published differentially expressed genes from 
these studies was avoided. This was to ensure consistent analy-
ses rather than rely on different statistical tests and to enforce 
the same stringency threshold.25,26 The use of data extracted 
from more than one experiment filters out false positives 
and narrows down the list of genes that show a significantly 
Table 2 Fold changes (log2 transformed) and corrected 
P-values (calculated by genespring gX) for genes involved 
in the T helper 17 and regulatory T cell signaling pathways 
and upregulated and/or downregulated
Probe ID Gene 
symbol
Gene  
description
Lesional versus 
nonlesional
Log2 fold 
change
Corrected 
P-value
208991_at sTaT3 signal transducer  
and activator of  
transcription 3
1.229 2.84e-05
208992_s_at sTaT3 signal transducer  
and activator of  
transcription 3
1.469 4.07e-07
209543_s_at cD34 cluster of  
differentiation 34
-1.046 1.67e-05
202859_x_at il8 interleukin 8 2.686 1.17e-05
205476_at ccl20 c-c motif  
ligand 20
1.932 7.39e-07
Notes: Positive and negative values of fold changes indicate upregulation and 
downregulation, respectively. Data were extracted and analyzed from the gse6710 
experiment.8 
Table 3 Fold changes (log2 transformed) and corrected P-values 
(calculated by genespring gX) for genes involved in the T helper 17 
and regulatory T cell signaling pathways and upregulated and/or 
downregulated
Probe ID Gene 
symbol
Gene  
description
Lesional versus 
nonlesional
Log2 fold 
change
Corrected 
P-value
208992_s_at sTaT3 signal transducer  
and activator of  
transcription 3
1.132 1.02e-28
39402_at il1B interleukin 1 beta 1.104 9.79e-23
205476_at ccl20 c-c motif  
ligand 20
2.889 2.99e-35
205798_at il7r interleukin 7  
receptor
1.266 6.91e-16
207861_at ccl22 c-c motif  
chemokine 22
1.032 7.31e-25
209774_x_at cXcl2 chemokine  
c-X-c motif  
ligand 2
1.831 1.27e-24
211506_s_at il8 interleukin 8 2.582 2.64e-17
216598_s_at ccl2 chemokine c-c  
motif ligand 2
1.436 1.95e-18
203936_s_at MMP9 Matrix 
metallopeptidase 9
1.486 6.18e-29
Notes: Positive and negative values of fold changes indicate upregulation and 
downregulation, respectively. Data are extracted and analyzed from the gse13355 
experiment.15
Table 4 Fold changes (log2 transformed) and corrected P-values 
(calculated by genespring gX) for genes involved in the T helper 17 
and regulatory T cell signaling pathways and upregulated and/or 
downregulated
Probe ID Gene 
symbol
Gene  
description
Lesional versus 
nonlesional
Log2 fold 
change
Corrected 
P-value
208991_at sTaT3 signal transducer  
and activator of  
transcription 3
1.169 4.17e-15
208992_s_at sTaT3 signal transducer  
and activator of  
transcription 3
1.247 1.04e-13
39402_at il1B interleukin 1 beta 1.191 5.86e-09
205758_at cD8a cluster of  
differentiation 8a
1.001 3.51e-11
202859_x_at il8 interleukin 8 3.606 5.22e-11
205476_at ccl20 c-c motif  
ligand 20
2.664 4.69e-15
205798_at il7r interleukin 7  
receptor
2.012 1.03e-12
207861_at ccl22 c-c motif  
chemokine 22
1.210 4.22e-10
209774_x_at cXcl2 chemokine  
c-X-c motif  
ligand 2
1.870 7.91e-12
216598_s_at ccl2 chemokine c-c  
motif ligand 2
1.345 2.62e-07
213539_at cD3D T cell surface  
glycoprotein  
cD3 delta chain
1.282 3.04e-11
203936_s_at MMP9 Matrix  
metallopeptidase 9
1.600 3.96e-11
Notes: Positive and negative values of fold changes indicate upregulation and 
downregulation, respectively. Data are extracted and analyzed from the gse14905 
experiment.16 
Network analysis was also performed on significant 
differentially expressed genes in each of the three data sets 
investigated, ie, GSE6710, GSE14905, and GSE13355 
 (significant = two-fold upregulated/downregulated in lesional 
versus nonlesional skin with a false discovery rate ,0.05). 
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altered expression level as a result of the disease. Moreover, it 
decreases the chance of drawing incorrect conclusions because 
the data are not generated from one laboratory. In 2005, Irizarry 
et al27 demonstrated that there are relatively large differences 
in data obtained from different laboratories, even between 
those using the same platform, but the results from the best 
performing laboratories agree rather well.
Genes that show significant overexpression in psoriatic 
skin were functionally annotated on human Kegg pathways 
(Tables S1 and S2). These genes need further investigation 
with other techniques and may provide insights into patho-
genesis or novel therapeutic targets.
In effect, and despite many efforts, the network of genes that 
shows significantly altered expression in psoriasis and represents 
the molecular signature of the disease is still  inconspicuous. 
This is manifested by the relatively high number of recent 
studies that focused on reanalysis of published data as well as 
designing new experiments. In 2009,  Gudjonsson et al28 reported 
some transcriptional differences between uninvolved skin from 
psoriatic patients as opposed to skin from normal individuals. 
Cluster analysis of transcripts with significantly altered expres-
sion identified a group of genes involved in lipid metabolism 
with highly correlated gene expression. Their results suggest 
decreased lipid biosynthesis and increased innate immunity in 
uninvolved psoriatic skin.
In 2010, the same group29 performed a gene expression 
study of 58 paired lesional and uninvolved psoriatic and 64 
control skin samples. Comparison of involved psoriatic and 
IL8
L13RA1
STAT3 IL1B
SYK
IL7R
ARG1
SOCS3
GZMB
CD8A
KRT6A
KRT17
CCL20
CCL22
KYNU
RRM2
CDC2
CDC20
CCNB1
CCNA2
CCL2
CD3D
IL12RB2
ALOX12B
STAT1
MMP9
Figure 2 network analysis (netanalyse.py method, setting shortest path threshold =1 and P-value threshold =0.05) shows possible interaction between the potential gene 
targets for treatment of psoriasis as identified in this study. Green circles indicate downregulated genes, orange/red circles indicate upregulated genes and small gray circles 
indicate part of the T helper 17/regulatory T cell pathway, but were not found to be affected in the experiments analyzed in this study. Lines between nodes show known 
direct interactions between genes. The network was edited in cytoskape, with a force-directed layout applied. nodes showing affected genes were enlarged and direct 
interactions between these nodes were highlighted in red to highlight the relevant interactions identified in this analysis in the context of the T helper 17/regulatory T cell 
pathway.
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normal skin identified new differentially regulated transcripts. 
Enriched gene ontology categories included immune response, 
defense response, and keratinocyte differentiation. In 2012, 
Tian et al30 adopted a statistically-based meta-analytic 
approach, which combines the results of individual studies 
to overcome the problem of having different lists of differen-
tially expressed genes across experiments due to variations 
introduced in the microarray pipelines. Their method differs 
from our approach since we have not combined the disparate 
microarray studies to derive a single estimate of the overall 
differential expression level for each gene. Instead, we reana-
lyzed each individual experiment using the same tools and 
criteria and listed the differentially expressed genes found in 
common to overcome the problem of getting false positives. 
The list of differentially expressed genes found in common is a 
limited set, and in particular, is limited only to genes featured 
on the less comprehensive array platform (GPL96 Affymetrix 
Human Genome U133A GeneChip). Combining data from 
different experiments into one pool is confounded by the 
inherent differences in platforms and probe sets and the effects 
of laboratory conditions. Further, our approach was notably 
different from others in that we extended our search to test a 
clinical hypothesis that altered transcriptional activity of the 
genes controlling the active interplay between T
H
17 and T
Reg
 
cells is important in disease expression.
This contemporary paradigm for psoriasis is supported 
by other recent studies. Krueger et al31 investigated the effect 
that neutralization of the T
H
17 cell cytokine, IL-17, has on the 
clinical features of psoriasis using quantitative real-time poly-
merase chain reaction and microarrays. Their results suggest 
that IL-17 is a key “driver” cytokine that activates pathogenic 
inflammation in psoriatic subjects. They also highlighted that 
neutralizing IL-17 with the anti-IL-17 monoclonal antibody, 
ixekizumab, might be a successful therapeutic strategy 
in  psoriasis.31 Concomitantly, two studies32,33 have been 
published in which the gene expression signature was used 
to stratify lesions and reveal distinct molecular subgroups 
within the clinical phenotype of plaque psoriasis. This is 
a new direction that will be very important in developing 
personalized medication for chronic disease.
Our study is also focused on expression of the genes 
underlying the balance between T
H
17 and T
Reg
 cells. Signal 
transducer and activator of transcription (STAT3, a member 
of the JAK-STAT signaling pathway), and the chemokines 
IL-8 and chemokine (C-C motif) ligand 20 (CCL20) were 
found to be upregulated in the three experiments. These 
results are in accordance with previously published data.34–36 
Recently, Miyoshi et al37 showed that use of STA-21, a small 
STAT3 inhibitor, was useful in ameliorating psoriatic skin 
lesions, not only in K5.Stat3C transgenic mice but also in 
humans. These results emphasize the importance of targeting 
STAT3 in the quest for new treatments of psoriasis. Similarly, 
ABX-IL8 is a fully human IgG
2
 monoclonal antibody that 
binds to human IL-8 with high affinity and specificity and 
is currently in Phase II clinical investigation for treatment 
of psoriasis by Abgenix (Fremont, CA, USA).38 Strikingly, 
Kim et al39 found that pretreatment with fluvastatin and sim-
vastatin inhibited migration of human CD4+T cells towards 
CCL20 in a chemotaxis migration assay. These findings 
suggest that these drugs may be of benefit in alleviating 
psoriasis via interrupting the CCL20/chemokine receptor 6 
(CCR6) chemotactic interaction, thus inhibiting infiltration 
of T
H
17 cells.
Other chemokines known to be related to T
H
17 and T
Reg
 
signaling pathways and found to be differentially upregu-
lated in lesional skin samples in at least one of the three 
experiments are CCL2, CCL22, chemokine (C-X-C motif) 
ligand 2 (CXCL2), and matrix metallopeptidase 9 (MMP9). 
CCL2 is expressed by keratinocytes in both atopic dermatitis 
and psoriasis and when stimulated with TNF-α and/or inter-
feron gamma (IFN-γ) in a dose-dependent manner.40 CCL2 
binds to the chemokine receptor CCR2 on monocytes and 
macrophages. CCR2 is overexpressed in monocytes from 
patients with psoriasis and atopic dermatitis. Thus, CCL2 and 
CCR2 interaction is likely to be of importance for monocyte/
macrophage trafficking.
CCL22 also belongs to the C-C motif family and is syn-
thesized and secreted by macrophages, dendritic cells, and 
osteoclasts. It acts selectively on chronically activated lym-
phocytes by interacting with the CCR4 receptor.  Traditionally, 
CCR4 has been reported to be expressed preferentially on 
T cells belonging to the Th2 subpopulation. Recent studies 
have also shown expression of CCR4 on T
H
17 cells as well as 
on T
Reg
 cells.41 The macrophage-derived chemokine/CCL22 
was found to be elevated in the synovial fluid of patients with 
rheumatoid arthritis and psoriatic arthritis, suggesting that 
CCR4 could play a role in attracting skin-specific memory 
T cells to the joints.42
MMP9 belongs to a family of proteolytic enzymes that 
are capable of degrading all components of the extracellular 
matrix, a key event in the development of cartilage destruction 
and joint erosion, and may play a part in psoriatic arthritis. In 
2006, Cordiali-Fei et al43 observed that MMP9 was decreased, 
along with clinical improvement in the lesional skin and sera 
of psoriatic patients receiving  infliximab, the anti-TNF-α 
monoclonal antibody. MMP9 may directly sustain the 
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inflammatory process and tissue destruction or contribute 
by allowing the traffic of inflammatory cells and enhancing 
the activity of inflammatory cytokines.
CXCL2 was reported to increase by two-fold in psoriatic 
versus atopic dermatitis skin.44 Bowcock and Cookson44 
 proposed that the higher expression of chemokines in pso-
riasis is among other factors that could sustain chronic T cell 
activation and persistence within focal skin regions.
Interestingly, our analysis did not show that all genes 
relating to the T
H
17 network (listed in Table 1) are differen-
tially expressed in lesional skin. In another similar study26 
where comparison of the expression of psoriasis-related 
genes across four different studies was conducted, some well 
recognized inflammatory genes involved in psoriasis, for 
example, IFN-γ, IL-17, and inducible nitric oxide synthase, 
were not detected. Using separate polymerase chain reaction, 
the authors showed that this may be due to low amplifica-
tion of these genes on the Affymetrix gene array platform 
(0–4 range of expression in log
2
 scale), and hence fold change 
is not accurately measured. As a positive control, this false 
negative finding suggests caution in interpreting gene array 
data. Most analysis pipelines filter out low abundance genes 
so they may be excluded from the statistical analysis, or the 
resultant fold change is very low, albeit significant. This is 
a major limitation of the use of these arrays for the study 
of these genes. Another possible explanation is that the 
expression was measured in bulk skin samples containing 
numerous cell types, and most of these genes are expressed 
in multiple cell types, so upregulation of a certain gene in one 
cell type may be neutralized by downregulation in another 
cell type.32
CD34, CD3D, and CD8A are the only surface receptor 
genes from the list in Table 1 that were found to be dif-
ferentially expressed in psoriatic lesions. CD34 was found 
in one experiment to be downregulated in lesional versus 
nonlesional skin (Table 2).
In our analysis, both CD3D and CD8A were found to be 
upregulated in lesional versus nonlesional skin. Both genes 
were previously reported to be downregulated in patients 
responding to alefacept, the LFA3-Ig fusion protein that 
binds to CD2.45
Other genes upregulated in our analysis (listed in Table 1) 
are IL-1β and IL-7R. In a previous study,46 IL-lβ was easily 
detectable by immunofluorescence microscopy and found 
to be localized predominantly in epidermal keratinocytes. 
Immunoreactive IL-lβ was found to be elevated in cytosolic 
extracts derived from involved psoriatic keratomes relative 
to keratomes of normal skin. The elevated IL-1β protein was 
accompanied by elevated levels of IL-lβ mRNA in psoriatic 
skin relative to normal skin. IL-7R expression is also known 
to increase by at least a two-fold magnitude in the peripheral 
blood cells of psoriatic patients when measured by cDNA 
microarray technology.47
Conclusion
Studies of gene expression profiling have the potential to 
greatly improve our understanding of the physiologic and 
molecular mechanisms underlying the pathogenesis and pro-
gression of psoriasis. However, the high chance of getting false 
positives has become a concern. Reanalysis of data extracted 
from different experiments using the same software and strin-
gent criteria could reduce this risk and thus refine the list of 
proposed new therapeutic targets. Our study also highlights 
the altered expression of genes known to be involved in the 
control of the T
H
17/T
Reg
 balance in psoriatic skin. By reanalyz-
ing repository data and specifically querying these pathways, 
we provide further evidence that this balance is of key impor-
tance in the etiopathogenesis and progression of psoriasis and 
demonstrate another approach to mining this data.
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Figure S1 network analysis (netanalyse.py method, setting shortest path threshold =1 and P-value threshold =0.05) shows possible interaction between the potential gene 
targets for treatment of psoriasis as identified in this study from the GSE6710 experiment.29 The network was edited in cytoskape, with a force-directed layout applied. 
green circles indicate downregulated genes, yellow-orange-red circles indicate upregulated genes, with red showing strongest and yellow showing least upregulation. size of 
the nodes indicates the level of significance, with larger nodes showing a lower FDR (higher significance). Lines connecting nodes show direct interactions between genes.
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Figure S2 network analysis (netanalyse.py method, setting shortest path threshold =1 and P-value threshold =0.05) shows possible interaction between potential gene 
targets for the treatment of psoriasis as identified in this study from the GSE13355 experiment.30 The network was edited in cytoskape, with a force-directed layout applied. 
green circles indicate downregulated genes, yellow-orange-red circles indicate upregulated genes, with red showing strongest and yellow showing least upregulation. size of 
the nodes indicates the level of significance, with larger nodes showing a lower FDR (higher significance). Lines connecting nodes show direct interactions between genes.
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Figure S3 Network analysis shows possible interaction between the potential gene targets for the treatment of psoriasis as identified in this study from the GSE14905 
experiment21 (green circles indicate downregulated genes and orange/red circles indicate upregulated genes).
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